Silexion Therapeutics reported Q3 2026 financial results, highlighting the dosing of the first patient in its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. The company strengthened its balance sheet through a public offering and warrant inducement, ending the quarter with $4.8 million in cash and $3.0 million in shareholders' equity.
Term
Q3 2026
“In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”
Ilan Hadar, Chairman and Chief Executive Officer
“During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”
Silexion Therapeutics Corp is a development-stage biotechnology company focused on its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. As of November 12, 2026, the company reported 649,528 ordinary shares outstanding and continues to operate as an emerging growth company with no product revenue to date.
Silexion Therapeutics Corp effected a 1-for-24 reverse share split of its ordinary shares effective after the close of trading on November 10, 2026. In connection with the split, the company adjusted its outstanding warrants, increasing the exercise price 24-fold to $372,600.00 per post-split share and reducing the number of shares issuable per warrant to 1/24th of a share.
Silexion Therapeutics announced a 1-for-24 reverse share split of its ordinary shares, effective after the market close on November 10, 2026. The split is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. Trading on a split-adjusted basis will begin on November 11, 2026, under the existing ticker symbol SLXN.
Silexion Therapeutics Corp shareholders approved a 1-for-24 reverse stock split of the company's ordinary shares, increasing the par value from $0.135 to $3.24 per share. Additionally, shareholders approved an increase in authorized share capital from 15.9 million to 515.9 million ordinary shares. The reverse split and capital increase were finalized at a reconvened extraordinary general meeting on October 26, 2026.